You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百誠醫藥(301096.SZ):截至2023年6月30日,賽默製藥累計已完成項目落地驗證270多個品種
格隆匯 01-18 18:01

格隆匯1月18日丨百誠醫藥(301096.SZ)於近期接受特定對象調研,就“子公司賽默製藥目前發展情況?”,公司回覆稱,賽默擁有藥品GMP標準的廠房及配套實驗室13.6萬平方米,生產劑型產線涵蓋口服固體制劑、小容量注射液、口服液體、眼用製劑(滴眼劑)、吸入製劑(含激素類)、原料藥、乳膏、凝膠、貼劑等多個劑型,產線豐富。截至2023年6月30日,賽默製藥累計已完成項目落地驗證270多個品種,申報註冊133個品種,位居全國前列。目前賽默製藥接受國家局註冊核查8次,15個品種通過藥品註冊核查,接受浙江省藥品GMP符合性檢查7次,12條生產線通過GMP檢查。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account